Decision

Eli Lilly Canada Inc. v. Novopharm Limited, 2010 FCA 130 (Olanzapine*)

Justice Sharlow - 2010-05-21

Read full decision. Automatically generated summary:

This appeal is scheduled for hearing on June 21, 2010. The appellants (collectively “Lilly”) are seeking to reverse a judgment of the Federal Court (2009 FC 1018) which, among other things, declared Canadian Patent No. 2,041,113 invalid and dismissed Lilly’s claim against the respondent (“Novopharm”) for damages and other relief for infringement of the patent.

Decision relates to:

 

Canadian Intellectual Property